author-photo

Kenneth B. Gordon

Northwestern University
Medical College of Wisconsin
NorthShore University HealthSystem

290

Papers

16175

Citations

Citation Trend

Filter By

Papers (198) Sort By

Journal Conference Others

28096 Sustained improvement in general health-related quality of life and work productivity in patients with moderate to severe psoriasis treated with guselkumab: 5-year data from clinical trial VOYAGE 2

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Molecular and clinical effects of selective TYK2 inhibition with deucravacitinib in psoriasis.

2021 The Journal of Allergy and Clinical Immunology
Show All
- Source
- Cite
- Save
Citations (0)
27464 Bimekizumab vs adalimumab in plaque psoriasis: Higher efficacy translates into improvements in quality of life in the BE SURE multicenter, randomized, double-blinded phase 3 trial

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

2021 British Journal of Dermatology
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.

2021 Journal of Dermatological Treatment
Show All
- Source
- Cite
- Save
Citations (0)
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.

2021 The Lancet
Show All
- Source
- Cite
- Save
Citations (31)
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.

2021 The Lancet
Show All
- Source
- Cite
- Save
Citations (23)
27629 Malignancy rates through 4 years of follow-up in guselkumab-treated moderate to severe psoriasis patients from the VOYAGE 1 and 2 trials and comparisons to the general United States population

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Number Needed to Treat Among Therapies for Patients with Moderate to Severe Plaque Psoriasis: Clinical Perspective of Results from a Network Meta-Analysis

2021
Show All
- Source
- Cite
- Save
Citations (0)
28095 Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (2)